Sunovion Pharmaceuticals Inc. Presents New Health Outcomes Data Supporting Brovana (Arformoterol Tartrate) Inhalation Solution In People With Moderate-To-Severe COPD At The 2016 American Thoracic Society International Conference

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that new analyses of clinical and health outcomes data for Brovana® (arformoterol tartrate) Inhalation Solution will be presented at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13-18, 2016 in San Francisco, Calif. The company will present post-hoc analyses using data from a long-term safety study evaluating BROVANA use in people with moderate-to-severe chronic obstructive pulmonary disease (COPD). Results from a prospective health outcomes study assessing the prevalence of low peak inspiratory flow rate among real world COPD patients will also be presented at the meeting.

Back to news